From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
S33005 structure.png
Clinical data
Other names(–)-1-(1-dimethylaminomethyl) 5-methoxybenzocyclobutan-1-yl) cyclohexanol
PubChem CID
Chemical and physical data
Molar mass289.41248 g/mol g·mol−1
3D model (JSmol)

S33005 is a serotonin–norepinephrine reuptake inhibitor (SNRI) that was under development by Servier for the treatment of depression and related disorders. It is structurally related to venlafaxine but has a more complex molecular structure. Venlafaxine appears to be a sigma modulator,[1] but it is not known if S33005 shares this activity.


"The 1-cyano-benzocyclobutenes used as starting material are obtained, for example, by subjecting a β-[orthohalogeno-phenyl]-propionitrile to intramolecular condensation in the presence of potassium amide, or by brominating a benzocyclobutene in position 1 with N-bromosuccinimide, followed by exchange of the bromine atom for a cyano group by means of sodium cyanide."[2]

See also[edit]


  1. ^ Dhir, Ashish; Kulkarni, S.K. (June 2007). "Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine". Neuroscience Letters. 420 (3): 204–208. doi:10.1016/j.neulet.2007.04.055. PMID 17532136.
  2. ^ U.S. Patent 3,622,614

External links[edit]